Isabel Kalofonos - 15 Oct 2026 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Reporting relationship: Chief Commercial Officer
Issuer ticker: CGON
Reported as of: 15 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Oct 2026, 16:30:09 UTC
Prior SEC filing: 19 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua F. Patterson, Attorney-in-Fact for Isabel Kalofonos

Filing notes and source

Key filing fact

Isabel Kalofonos filed Form 4 for CG Oncology, Inc. (CGON) on 19 Oct 2026.

Key facts

This page summarizes Isabel Kalofonos's Form 4 filing for CG Oncology, Inc. (CGON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Oct 2026, 16:30.

Change

Previous filing in this sequence was filed on 19 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001975163 Primary reporting owner

Kalofonos Isabel

Relationship: Chief Commercial Officer
Address: C/O CG ONCOLOGY, INC., 3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS
Signature: /s/ Joshua F. Patterson, Attorney-in-Fact for Isabel Kalofonos
Signature date: 19 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGON transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +92,000
Change %
Price: $0.000000^*
Shares after: 92,000
Date: 15 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 92,000
Exercise price: $61.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests over a four-year period starting on October 13, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period, subject to the Reporting Person's continuous service to the Issuer through each vesting date.